Mycophenolate Mofetil/Mycophenolate Sodium
First approved in the United States in 1995 for use in kidney transplantation. It can be used in combination with other immunosuppressant’s.
Biomyf is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants
Mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune disease. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis
Mycophenolate Mofetil 500mg / Mycophenolate Sodium 360mg
MODE OF ACTION:
Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5′-monophosphate dehydrogenase.
MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, there by suppressing cell-mediated immune responses and antibody formation.
The active metabolite of mycophenolate, mycophenolic acid, prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA. MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferential inhibition of IMPDH II. Mycophenolate mofetil reduces de-novo production of guanosine nucleotides, interfering with the synthesis of DNA, RNA, and protein required for immune cell production
- Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants.
- Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.
- Systemic lupus erythematosus
- Pemphigus vulgaris
- Pemphigus vulgaris
- Myasthenia gravis
- Sjögren's disease
- Uveitis and vasculitis
Prophylaxis of organ rejection in patients receiving allogeneic renal transplants; use concomitantly with cyclosporine and corticosteroids
Mycophenolate mofetil (MMF): 1 g PO/IV q12hr, infused over ≥2 hours
- MMF: In severe renal impairment (glomerular filtration rate [GFR] <25
mL/min/1.73 m²), not to exceed 1 g q12hr
- No dosage adjustment needed in renal transplant patients experiencing delayed graft function postoperatively
Lupus Nephritis (Off-label)
- Induction therapy for lupus nephritis (MMF)
- Induction: 1 g PO q12hr with a glucocorticoid or 2-3 g for 6 months with glucocorticoids
- Maintenance: 0.5-3 g/day or 1 g PO q12hr or 1-2 g daily
- Administer with initial IV corticosteroid pulse for 3 days, then prednisone 0.5-1 mg/kg/day PO; not to exceed 10 mg/day; after a few weeks, prednisone may be tapered to lowest effective dose
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.